JP2024088642A5 - - Google Patents

Download PDF

Info

Publication number
JP2024088642A5
JP2024088642A5 JP2024037589A JP2024037589A JP2024088642A5 JP 2024088642 A5 JP2024088642 A5 JP 2024088642A5 JP 2024037589 A JP2024037589 A JP 2024037589A JP 2024037589 A JP2024037589 A JP 2024037589A JP 2024088642 A5 JP2024088642 A5 JP 2024088642A5
Authority
JP
Japan
Prior art keywords
segment
modification
edited
composition
editing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024037589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024088642A (ja
Filing date
Publication date
Priority claimed from JP2021070537A external-priority patent/JP2021119776A/ja
Application filed filed Critical
Publication of JP2024088642A publication Critical patent/JP2024088642A/ja
Publication of JP2024088642A5 publication Critical patent/JP2024088642A5/ja
Pending legal-status Critical Current

Links

JP2024037589A 2016-05-06 2024-03-11 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法 Pending JP2024088642A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662333004P 2016-05-06 2016-05-06
US62/333,004 2016-05-06
US201662410487P 2016-10-20 2016-10-20
US62/410,487 2016-10-20
JP2021070537A JP2021119776A (ja) 2016-05-06 2021-04-19 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2022167056A JP2023011676A (ja) 2016-05-06 2022-10-18 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022167056A Division JP2023011676A (ja) 2016-05-06 2022-10-18 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法

Publications (2)

Publication Number Publication Date
JP2024088642A JP2024088642A (ja) 2024-07-02
JP2024088642A5 true JP2024088642A5 (enExample) 2025-03-07

Family

ID=60203506

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018558207A Active JP6872560B2 (ja) 2016-05-06 2017-05-05 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2021070537A Pending JP2021119776A (ja) 2016-05-06 2021-04-19 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2022167056A Pending JP2023011676A (ja) 2016-05-06 2022-10-18 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2024037589A Pending JP2024088642A (ja) 2016-05-06 2024-03-11 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2018558207A Active JP6872560B2 (ja) 2016-05-06 2017-05-05 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2021070537A Pending JP2021119776A (ja) 2016-05-06 2021-04-19 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法
JP2022167056A Pending JP2023011676A (ja) 2016-05-06 2022-10-18 プログラム可能ヌクレアーゼのあるゲノム編集及びプログラム可能ヌクレアーゼのないゲノム編集のための改善された方法

Country Status (6)

Country Link
US (1) US20190300872A1 (enExample)
EP (2) EP3452055A4 (enExample)
JP (4) JP6872560B2 (enExample)
CN (1) CN109414449A (enExample)
CA (1) CA3022319A1 (enExample)
WO (1) WO2017193053A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
JP6997623B2 (ja) * 2014-12-12 2022-02-04 エム. ウルフ、トッド オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
WO2017193053A1 (en) * 2016-05-06 2017-11-09 Woolf Tod M Improved methods for genome editing with and without programmable nucleases
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのaav送達
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
BR112020013848A2 (pt) 2018-01-08 2020-12-01 Iovance Biotherapeutics, Inc. métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
AU2019255725A1 (en) * 2018-04-18 2020-12-10 Ligandal, Inc. Methods and compositions for genome editing
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20210079387A1 (en) * 2019-08-27 2021-03-18 The Jackson Laboratory Cleavage-resistant donor nucleic acids and methods of use
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
EP4103740A1 (en) * 2020-02-10 2022-12-21 Palogen, Inc. Nanopore device and methods of detecting and classifying charged particles using same
CN111378051B (zh) * 2020-03-25 2022-03-01 北京市农林科学院 Pe-p2引导编辑系统及其在基因组碱基编辑中的应用
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN116261461A (zh) * 2020-07-30 2023-06-13 新加坡科技研究局 刺激细胞增殖的方法
US20220056437A1 (en) * 2020-08-19 2022-02-24 Integrated Dna Technologies, Inc. Methods and compositions for inhibition of crispr re-cleavage events
CN113637670A (zh) * 2021-04-27 2021-11-12 中国药科大学 一种用于任意基因表达调控的组合物及方法
CA3237003A1 (en) * 2021-11-01 2023-05-04 George Mcdonald Church Dna revertase
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
DK0452457T3 (da) 1989-11-03 1998-03-02 Univ Vanderbilt Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
AU2522095A (en) 1994-05-19 1995-12-18 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
AU4948801A (en) 2000-03-27 2001-10-08 Univ Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP4665758B2 (ja) 2003-04-22 2011-04-06 国立大学法人九州大学 チオヌクレオシド−s−ニトロシル誘導体
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
CN104975020B (zh) 2008-02-11 2020-01-17 菲奥医药公司 经修饰的RNAi多核苷酸及其用途
AU2009336191B2 (en) 2008-12-18 2017-08-24 Novo Nordisk A/S Extended dicer substrate agents and methods for the specific inhibition of gene expression
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US8309356B2 (en) 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
CA2794187C (en) 2010-03-24 2020-07-14 Rxi Pharmaceuticals Corporation Rna interference in ocular indications
EP2616543A1 (en) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
US10555911B2 (en) 2012-05-04 2020-02-11 Yale University Highly penetrative nanocarriers for treatment of CNS disease
SI3401400T1 (sl) * 2012-05-25 2019-10-30 Univ California Postopki in sestavki za RNA usmerjeno modifikacijo tarčne DNA in za RNA usmerjeno modulacijo prepisovanja
SI2852668T1 (sl) * 2012-07-12 2016-09-30 Proqr Therapeutics Ii B.V. Oligonukleotidi za izvedbo spremembe v sekvenci tarčne molekule rna, prisotne v živeči celici
BR112015022829B1 (pt) * 2013-03-15 2022-06-14 Cibus Europe B.V. Método para a introdução de uma mutação mediada por oligonucleobase de reparação de gene (gron) em uma sequência alvo de ácido desoxirribonucleico (dna) em uma célula vegetal
US9234213B2 (en) * 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
US9840699B2 (en) * 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
SG11201609211VA (en) * 2014-03-05 2016-12-29 Nat Univ Corp Univ Kobe Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
ES2974625T3 (es) * 2014-03-14 2024-06-28 Cibus Us Llc Procedimientos y composiciones para aumentar la eficacia de la modificación génica dirigida mediante reparación génica mediada por oligonucleótidos
EP3800248A3 (en) * 2014-04-18 2021-08-04 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3186376B1 (en) * 2014-08-27 2019-03-20 Caribou Biosciences, Inc. Methods for increasing cas9-mediated engineering efficiency
US20170233762A1 (en) * 2014-09-29 2017-08-17 The Regents Of The University Of California Scaffold rnas
EP3561052A1 (en) * 2014-10-15 2019-10-30 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
JP6997623B2 (ja) * 2014-12-12 2022-02-04 エム. ウルフ、トッド オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法
EP3322804B1 (en) * 2015-07-15 2021-09-01 Rutgers, The State University of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
WO2017193053A1 (en) * 2016-05-06 2017-11-09 Woolf Tod M Improved methods for genome editing with and without programmable nucleases

Similar Documents

Publication Publication Date Title
JP2024088642A5 (enExample)
EP1937312B1 (en) Chimeric oligomeric compounds for modulation of splicing
JP2024038327A5 (enExample)
JP2023507521A (ja) シュタルガルト病の処置におけるヌクレオチド脱アミノ化のためのアンチセンスオリゴヌクレオチド
JP2024105284A5 (enExample)
JPWO2019237069A5 (enExample)
JPWO2019217784A5 (enExample)
CN101448945A (zh) 用于诱导外显子跳跃的手段和方法
EP3643783A1 (en) Compositions and methods for modulation of smn2 splicing in a subject
JP2009514877A5 (enExample)
CN105452461B (zh) 生长激素受体的调节剂
JP2018516091A5 (enExample)
JP2016530882A5 (enExample)
JP2009532392A5 (enExample)
JP2006502694A5 (enExample)
JP2005501557A5 (enExample)
JP2016520312A5 (enExample)
JPWO2020069296A5 (enExample)
JP2020503017A5 (enExample)
JP7553036B2 (ja) snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤
JP2006502243A5 (enExample)
WO2023205708A1 (en) SITE SPECIFIC GENETIC ENGINEERING UTILIZING TRANS-TEMPLATE RNAs
JP2019527549A5 (enExample)
JPWO2021188390A5 (enExample)
JPWO2023081687A5 (enExample)